Five Prime Therapeutics, an early clinical stage biotech developing protein therapeutics, filed on Friday with the SEC to raise up to $60 million in an initial public offering. Its backers include Pfizer (13.7% pre-IPO stake), Advanced Technology Ventures (9.1%), Domain Associates (9.1%), HealthCap (9.1%), KPCB (9.1%), Texas Pacific Group (9.1%), Versant Ventures (9.1%) and GSK (6.3%).
The San Francisco, CA-based company, which was founded in 2001 and booked $26 million in collaboration for the 12 months ended June 30, 2013, plans to list on the NASDAQ under the symbol FPRX. Five Prime Therapeutics initially filed confidentially on June 14, 2013. Jefferies & Co., BMO Capital Markets and Wells Fargo Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
